Treatment of severe hypoglycaemic reactions ( low blood glucose) , which may occur in the management of insulin treated persons with diabetes mellitus.
How it works
Glucagon binds the glucagon receptor, a G protein-coupled receptor located in the plasma membrane, which then initiates a dual signaling pathway using both adenylate cyclase activation and increased intracellular calcium. Adenylate cyclase manufactures cAMP (cyclic AMP), which activates protein kinase A (cAMP-dependent protein kinase). This enzyme, in turn, activates phosphorylase kinase, which, in turn, phosphorylates glycogen phosphorylase, converting into the active form called phosphorylase A. Phosphorylase A is the enzyme responsible for the release of glucose-1-phosphate from glycogen polymers.
Common side effects
Vomiting, Nausea, Hypersensitivity reaction, Decreased potassium level in blood, Tachycardia